Valerian Root: The Definitive Guide

What is valerian root?

Valerian root is the dry root or root-and-rhizome of Valeriana officinalis. It is sold as tea, powder, tincture, fluid extract and dry extract. Other valerian species and multi-herb sleep formulas are separate products. [1], [2]

Health Canada's July 2024 monograph recognizes traditional use for nervousness or restlessness and to promote sleep. A traditional licensing claim is not proof that valerian treats chronic insomnia. [1]

The most current high-level synthesis is cautious. A 2024 umbrella review found no evidence of efficacy for insomnia and concluded that apparent subjective sleep-quality improvement has not been demonstrated with quantitative or objective measurements. [3]

Typical Valerian Root Protocols

There is no RDA, AI or established UL for valerian. The Health Canada maximum of 12 g/day dried equivalent and 3.6 g per dose describes licensed-product boundaries across preparations. It is not a self-escalation goal. [1]

Titration

No validated self-titration is established. Different extracts and trial amounts cannot be arranged into a universal step-up schedule.

Timing

Health Canada directs sleep-aid products 30–60 minutes before bedtime as needed. Daytime use can still impair driving or work.

Duration

Trials range from a single dose to eight weeks. Long-term safety and continued benefit remain uncertain.

Stopping

No standard taper is established. People using high amounts for long periods or combining sedatives should make changes with a clinician rather than assume withdrawal is impossible.

What is valerian root commonly used for?

People use valerian for sleep onset, nighttime waking, nervousness and restlessness. Public use is common, but popularity and traditional authorization do not establish treatment of insomnia.

The 2020 review included 60 studies and reported possible subjective sleep-quality and anxiety signals, while attributing inconsistency partly to variable extract quality. The later 2024 umbrella review restricted itself to reviews and concluded there was no empirical support for insomnia efficacy. The later synthesis provides the safer overall interpretation. [3], [4]

Sleep complaints are not one condition. Menopause, cancer treatment, circadian disruption, sleep apnea, restless legs, pain, medication effects and mood disorders can produce different symptoms and responses.

Which form and label details matter?

1. Species: look for Valeriana officinalis.
2. Part: root or root and rhizome; do not substitute an unspecified whole plant.
3. Preparation: tea, powder, tincture, aqueous extract and hydroalcoholic extract differ.
4. Dried equivalent: compare the finished-extract amount with the represented root amount.
5. Standardization: Health Canada permits 0.05–0.90% valerenic acid or 0.10–0.90% sesquiterpenic acids for standardized paths. Marker percentage does not prove clinical equivalence. [1]
6. Other sedatives: melatonin, hops, passionflower, lemon balm and medicines change attribution and impairment risk.

What does the human evidence show?

Overall insomnia evidence

Valente and colleagues identified eight eligible systematic reviews. They found no evidence of efficacy for insomnia, although subjective sleep quality may improve. Quantitative and objective measures did not establish effectiveness, and the underlying studies were scarce, heterogeneous and often low quality. [3]

Shinjyo and colleagues reviewed 60 studies involving 6,894 participants and reported pooled subjective sleep-quality signals with differences by whole-root versus extract preparations. That broader review included associated disorders and combinations. Its favorable conclusion does not override product heterogeneity or establish an objective insomnia effect. [4]

Null and population-specific trials

Taibi and colleagues studied 16 older women using 300 mg 30 minutes before bed for two weeks per crossover period. No self-reported, polysomnographic or actigraphic outcome differed from placebo; wake after sleep onset increased from baseline with valerian. [5]

In the oncology trial, 227 people were randomized and 119 were evaluable for the primary endpoint. Valerian 450 mg one hour before bed for eight weeks did not improve the prespecified PSQI area-under-the-curve result. Exploratory fatigue and symptom signals need confirmation. [6]

A 100-person postmenopausal trial reported questionnaire sleep-quality improvement with 530 mg twice daily for four weeks. The specific population, subjective endpoint and twice-daily exposure limit generalization. [7]

Newer extract-specific evidence

The Shekhar trial randomized 80 adults with mild sleep complaints to 200 mg of a proprietary extract standardized to 2% valerenic acid or placebo one hour before bed for eight weeks. PSQI, wrist-actigraphy measures and polysomnography in a 20-person-per-group subset favored the extract. The exact product and mild-symptom population matter, and one positive trial does not overturn the 2024 umbrella conclusion. [8]

Donath's 16-person crossover tested LI 156 at 600 mg as a single dose and after 14 days. Selected repeated-dose sleep-structure and sleep-perception findings were favorable. Its size and product specificity prevent a general 600 mg recommendation. [9]

How might it work?

Valerian contains valerenic acids, volatile oils and other constituents. Laboratory hypotheses include GABA-related signaling, but there is no scientific agreement on one active constituent or mechanism. [2]

Extraction, storage and plant material change constituent content. Receptor assays and marker percentages cannot determine whether a retail product improves insomnia.

What are the risks and interactions?

Reported effects include headache, dizziness, itching and gastrointestinal symptoms. Morning sleepiness increased after 900 mg in one study summarized by NIH ODS. Long-term safety data are limited. [2]

Health Canada says to avoid alcohol and products that cause drowsiness and to use caution driving or operating machinery. Additive impairment is plausible with benzodiazepines, opioids, barbiturates, propofol, sedating antihistamines, cannabis, melatonin and calming herbs. [1], [2]

Pregnancy and breastfeeding require professional advice because risks have not been adequately evaluated. Persistent sleeplessness beyond four weeks or worsening nervousness warrants assessment. [1], [2]

Seek urgent care for breathing difficulty, facial or throat swelling, fainting, profound confusion, suicidal thoughts, severe unsteadiness or suspected overdose.

Legal status in the United States and Canada

In the United States, valerian is sold as a dietary supplement without FDA premarket approval for insomnia efficacy.

In Canada, licensed products carry an NPN. The July 2024 monograph specifies root identity, eligible preparations, licensing ranges, bedtime direction and sedation warnings. [1]

What should you monitor?

Record species, plant part, extract ratio, dried equivalent, marker percentage, amount, timing, start date and all sedating substances. Track sleep onset, awakenings, wake time, total sleep time, next-day drowsiness, dizziness and functioning.

Use the same sleep measure and a preset review date. Self-tracking cannot diagnose insomnia or prove causation, and improving a questionnaire score does not necessarily mean objective sleep improved.

What happens when you stop?

A predictable withdrawal syndrome is not established. Case reports cannot define incidence, but abrupt changes after prolonged high-dose use or sedative combinations deserve clinical guidance. Do not use valerian to manage benzodiazepine or alcohol withdrawal.

How should it be stored?

Follow the label. Keep root and extracts closed, dry, away from heat and out of children's reach. Volatile constituents and odor change with poor storage; discard damp, moldy or expired products.

How does valerian compare with other approaches?

Cognitive behavioral therapy for insomnia is a first-line treatment for chronic insomnia. Sleep scheduling and assessment for apnea, restless legs, medications, pain and mood disorders address causes valerian does not.

Melatonin addresses circadian timing in selected contexts and is not interchangeable with valerian. Passionflower, lemon balm, hops and combination formulas have distinct evidence; combination trials cannot isolate valerian.

What do public communities add?

Public discussions can reveal odor, taste, vivid dreams, next-day grogginess and sedative stacking. They cannot verify extract chemistry, diagnose insomnia or prove benefit. Reviews often combine tea, powder and standardized extracts as though equivalent.

Common questions

Does valerian treat insomnia?

The 2024 umbrella review found no evidence of insomnia efficacy. Subjective sleep quality may improve in some studies, but objective evidence is not established. [3]

Is 600 mg the proven best dose?

No. One very small study used 600 mg of LI 156, while other trials used different products and amounts. Product-specific schedules are not universal targets. [9]

Is the Health Canada range a recommendation?

No. It is a licensing range across preparations and traditional claims, with a maximum per-dose boundary. [1]

Can I combine it with alcohol or sleep medicines?

Health Canada says to avoid alcohol and products that cause drowsiness. Additive impairment is a concern. [1]

Can I drive after taking it?

Use caution. Drowsiness and dizziness can occur, including the next morning. [1], [2]

Is it safe long term?

Long-term safety is uncertain. Trials are generally short and do not establish indefinite use. [2], [3]

Is it safe during pregnancy or breastfeeding?

Risks have not been adequately evaluated. Health Canada and NIH ODS advise professional guidance. [1], [2]

Should I taper valerian?

No standard taper is established. Discuss changes after prolonged high-dose use or when other sedatives are involved.

Glossary

Terms used in this guide.

Rhizome

An underground stem included with root in some valerian preparations.

Dried equivalent

The amount of dried root represented by an extract dose.

PSQI

Pittsburgh Sleep Quality Index, a self-reported sleep questionnaire.

Actigraphy

Movement-based estimation of sleep and wake, usually from a wrist device.

Polysomnography

Laboratory measurement of sleep stages and physiologic signals.

Umbrella review

A review of systematic reviews rather than a direct pooling of individual trials.

Titration

Changing an amount in planned steps. No general valerian self-titration is established.

How this guide was researched

This draft used Health Canada's July 2024 monograph, NIH ODS, the 2024 umbrella review, the 2020 systematic review and primary trials in older women, oncology patients, postmenopausal women, adults with mild sleep complaints and psychophysiologic insomnia. Searches covered identity, preparation, objective and subjective outcomes, safety, sedation, pregnancy and interactions.

Corrections to the legacy manuscript include leading with the 2024 umbrella review's no-efficacy conclusion; removing a claimed universal 300–600 mg range and “600 mg sweet spot”; retaining null primary endpoints; separating proprietary-extract results; and removing unsupported dependence, mandatory taper and safer-than-prescription claims. Evidence was refreshed October 9, 2026.

How this guide was made

The source ledger records preparation, population, schedule, outcome, access level and limitations. Numeric rows rely on official or primary text. Draft status means scientific, French-parity, asset and rendered-page review remain separate gates.

Sources

Related guides